2m 2m 2m 2m 2m 2m 2m
RELMADA THERAPEU (RLMD)
NASDAQ
$3.24+$0.03 (+0.84%)
Price as of Oct 22, 2026 7:56 PM EDT- $342.4MMarket Cap
- 50.00%1-Year Change
- BiotechnologyIndustry
RELMADA THERAPEU (RLMD)
$3.24+$0.03 (+0.84%)
RLMD | vs History | vs S&P 500 | |
|---|---|---|---|
General Statistics | |||
Latest Close | $3.21 | ||
Change | -$0.15 (-4.46%) | ||
Open | $3.35 | ||
High | $3.40 | ||
Low | $3.19 | ||
Previous Close | $3.36 | ||
Volume | 1,720,536 | ||
30-Day Average Volume | 1,222,874 | ||
1-Week Change | -0.93% | ||
1-Month Change | -22.84% | ||
1-Year Change | 50.00% | ||
3-Year Change | 5.94% | ||
5-Year Change | -86.41% | ||
Fundamentals | |||
Shares Outstanding | 106.7M | ||
Total Assets | $219.1M | ||
Market Cap | $342.4M | ||
Enterprise Value | $331.1M | ||
Period: QTR TTM FY | |||
Revenue | -$204,552.00 | ||
Net Income | -$12.9M | ||
Free Cash Flow | -$9.6M | ||
EBIT | -$12.9M | ||
EBITDA | -$12.9M | ||
Net Working Capital | $211.6M | ||
EPS | -$0.11 | ||
Enterprise Value/EBITDA | -26 | ||
Enterprise Value/Revenue | -1,619 | ||
P/B | 2 | ||
P/E | -29 | ||
PEG | -1 | ||
Price/Free Cash Flow | -36 | ||
Price/Operating Cash Flow | -36 | ||
Dividends & Splits | |||
Forward Annual Dividend Yield | N/A | ||
Trailing Annual Dividend Yield | N/A | ||
Ex-Dividend Date | N/A | ||
Last Split Factor | 1 : 4 | ||
Last Split Date | 09/30/2019 | ||
Earnings & Revenue